Ratings for Moderna MRNA were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings ...

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...

Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new seasonal flu, and a combination seasonal flu/COVID vaccine. Moderna ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely ...

Moderna Bearish on Vaccines Despite Analyst Takes Rival vaccine manufacturer Moderna, for its part, felt bearish on vaccination rates at JPM. But Truist analysts Asthika Goonewardene and Karina ...

China's trade surplus grew to $104.84 billion in December, as exports rose faster than expected, according to official customs data released on Monday. Chinese factories rushed to complete orders ...

Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most ...

Copyright 2025 The Associated Press. All Rights Reserved. A local resident receives the Moderna COVID-19 vaccine shot at a center, June 30, 2021, in the Sumida ward ...

Moderna MRNA0.58%increase; green up pointing triangle set financial targets for 2025 as companies in the healthcare space rolled out corporate updates in conjunction with a health conference held ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

As for 2024, Moderna says it reeled in sales between $3 billion and $3.1 billion, a result that came in at the low end of the company’s previous guidance range of $3 billion to $3.5 billion ...